News archive
Showing 742 results
September 2017
-
Media Release
Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI… -
Media Release
Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
August 2017
-
Media Release
Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment… -
Media Release
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment… -
Media Release
Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media Release
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media Release
Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
- elevateMS study allows researchers to collect sensor-based movement data and symptoms directly from participants without the need for clinic visits- Study aims to improve understanding of daily… -
Media Release
Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
July 2017
-
Media Release
FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
AMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25… -
Media Release
FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media Release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
- 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis(1)- Data planned to be presented at a… -
Media Release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis